Clinical Exome Studies Have Inconsistent Coverage

Abstract BACKGROUND Exome sequencing has become a commonly used clinical diagnostic test. Multiple studies have examined the diagnostic utility and individual laboratory performance of exome testing; however, no previous study has surveyed and compared the data quality from multiple clinical laborat...

Full description

Saved in:
Bibliographic Details
Published in:Clinical chemistry (Baltimore, Md.) Md.), 2020-01, Vol.66 (1), p.199-206
Main Authors: Gotway, Garrett, Crossley, Eric, Kozlitina, Julia, Xing, Chao, Fan, Judy, Hornbuckle, Callie, Thies, Jenny, Michel, Donnice, Quinn, Christine, Scheuerle, Angela E, Umana, Luis A, Uhles, Crescenda L, Park, Jason Y
Format: Article
Language:English
Subjects:
Chromosomes
Comparative analysis
Conserved sequence
Consistency
Datasets
Diagnostic equipment (Medical)
Diagnostic systems
Epilepsy
Genes
Genomes
Information management
Laboratories
Medical laboratories
Nucleotides
Studies
Surveys
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract BACKGROUND Exome sequencing has become a commonly used clinical diagnostic test. Multiple studies have examined the diagnostic utility and individual laboratory performance of exome testing; however, no previous study has surveyed and compared the data quality from multiple clinical laboratories. METHODS We examined sequencing data from 36 clinical exome tests from 3 clinical laboratories. Exome data were compared in terms of overall characteristics and coverage of specific genes and nucleotide positions. The sets of genes examined included genes in Consensus Coding Sequence (CCDS) (n = 17723), a subset of genes clinically relevant to epilepsy (n = 108), and genes that are recommended for reporting of secondary findings (n = 57; excludes X-linked genes). RESULTS The average exome nucleotide coverage (≥20×) of each laboratory varied at 96.49% (CV = 3%), 96.54% (CV = 1%), and 91.68% (CV = 4%), for laboratories A, B, and C, respectively. For CCDS genes, the average number of completely covered genes varied at 12184 (CV = 29%), 11687 (CV = 13%), and 5989 (CV = 37%), for laboratories A, B, and C, respectively. With smaller subsets of genes related to epilepsy and secondary findings, the CV revealed low consistency, with a maximum CV seen in laboratory C for both epilepsy genes (CV = 60%) and secondary findings genes (CV = 71%). CONCLUSIONS Poor consistency in complete gene coverage was seen in the clinical exome laboratories surveyed. The degree of consistency varied widely between the laboratories.
ISSN:0009-9147
1530-8561
DOI:10.1093/clinchem.2019.306795